These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35379562)

  • 1. Does Changing the Age of a Child to be Considered in 3-Level Version of EQ-5D-Y Discrete Choice Experiment-Based Valuation Studies Affect Health Preferences?
    Ramos-Goñi JM; Estévez-Carrillo A; Rivero-Arias O; Rowen D; Mott D; Shah K; Oppe M
    Value Health; 2022 Jul; 25(7):1196-1204. PubMed ID: 35379562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective.
    Kreimeier S; Oppe M; Ramos-Goñi JM; Cole A; Devlin N; Herdman M; Mulhern B; Shah KK; Stolk E; Rivero-Arias O; Greiner W
    Value Health; 2018 Nov; 21(11):1291-1298. PubMed ID: 30442276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values.
    Fitriana TS; Roudijk B; Purba FD; Busschbach JJV; Stolk E
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):157-167. PubMed ID: 36348155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Adult and Adolescent Preferences Toward EQ-5D-Y-3L Health States.
    Prevolnik Rupel V; Ramos-Goñi JM; Ogorevc M; Kreimeier S; Ludwig K; Greiner W
    Value Health; 2021 Sep; 24(9):1350-1359. PubMed ID: 34452716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value Set for the EQ-5D-Y-3L in Hungary.
    Rencz F; Ruzsa G; Bató A; Yang Z; Finch AP; Brodszky V
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):205-215. PubMed ID: 36123448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valuing EQ-5D-Y-3L Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?
    Mott DJ; Shah KK; Ramos-Goñi JM; Devlin NJ; Rivero-Arias O
    Med Decis Making; 2021 Jul; 41(5):584-596. PubMed ID: 33733920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self vs. other, child vs. adult. An experimental comparison of valuation perspectives for valuation of EQ-5D-Y-3L health states.
    Lipman SA; Reckers-Droog VT; Karimi M; Jakubczyk M; Attema AE
    Eur J Health Econ; 2021 Dec; 22(9):1507-1518. PubMed ID: 34611793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EQ-5D-Y Value Set for Slovenia.
    Prevolnik Rupel V; Ogorevc M;
    Pharmacoeconomics; 2021 Apr; 39(4):463-471. PubMed ID: 33565048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values.
    Shah KK; Ramos-Goñi JM; Kreimeier S; Devlin NJ
    Eur J Health Econ; 2020 Sep; 21(7):1091-1103. PubMed ID: 32506281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Child health valuation protocol for a discrete choice experiment comparing paired comparison and kaizen tasks and estimating US EQ-5D-Y-3L values on an experience scale.
    Jumamyradov M; Craig BM; Rivero-Arias O; Jakubczyk M
    BMJ Open; 2023 Oct; 13(10):e077256. PubMed ID: 37879694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Value Set for the EQ-5D-Y-3L in the Netherlands.
    Roudijk B; Sajjad A; Essers B; Lipman S; Stalmeier P; Finch AP
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):193-203. PubMed ID: 36216977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan.
    Shiroiwa T; Ikeda S; Noto S; Fukuda T; Stolk E
    Med Decis Making; 2021 Jul; 41(5):597-606. PubMed ID: 33754886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International Valuation Protocol for the EQ-5D-Y-3L.
    Ramos-Goñi JM; Oppe M; Stolk E; Shah K; Kreimeier S; Rivero-Arias O; Devlin N
    Pharmacoeconomics; 2020 Jul; 38(7):653-663. PubMed ID: 32297224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EQ-5D-Y Value Set for Germany.
    Kreimeier S; Mott D; Ludwig K; Greiner W;
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):217-229. PubMed ID: 35604633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating an EQ-5D-Y-3L Value Set for Brazil.
    Espirito Santo CM; Miyamoto GC; Santos VS; Ben ÂJ; Finch AP; Roudijk B; de Jesus-Moraleida FR; Stein AT; Santos M; Yamato TP
    Pharmacoeconomics; 2024 Sep; 42(9):1047-1063. PubMed ID: 38954389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why Do Adults Value EQ-5D-Y-3L Health States Differently for Themselves Than for Children and Adolescents: A Think-Aloud Study.
    Reckers-Droog V; Karimi M; Lipman S; Verstraete J
    Value Health; 2022 Jul; 25(7):1174-1184. PubMed ID: 35168891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparatory study for the revaluation of the EQ-5D tariff: methodology report.
    Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A
    Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choice Defines QALYs: A US Valuation of the EQ-5D-5L.
    Craig BM; Rand K
    Med Care; 2018 Jun; 56(6):529-536. PubMed ID: 29668646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
    Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
    Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating an EQ-5D-Y-3L Value Set for China.
    Yang Z; Jiang J; Wang P; Jin X; Wu J; Fang Y; Feng D; Xi X; Li S; Jing M; Zheng B; Huang W; Luo N
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):147-155. PubMed ID: 36396878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.